NASDAQ:APGE

Apogee Stock in Focus After Blackstone Announces $1.3 Billion Deal
····

Apogee Stock in Focus After Blackstone Announces $1.3 Billion Deal

Apogee Therapeutics secured up to $1.3 billion in funding from Blackstone Life Sciences to advance its eczema drug zumilokibart through late-stage trials. Shares closed nearly flat at $77.82 after earlier declines on drug data. In a Phase 2 trial, 65.9% of patients on the mid dose reached the main efficacy target. The company plans to move the mid dose into Phase 3 in late 2026.
May 29, 2026

Stock Market Today

  • Yindjibarndi Leader Michael Woodley Rejects $150M Compensation from Fortescue Metals Group
    May 28, 2026, 7:01 PM EDT. Michael Woodley, CEO of the Yindjibarndi Ngurra Aboriginal Corporation, refuses to fully accept $150 million compensation awarded to the Yindjibarndi people by the Federal Court in Australia. The payout, ordered against Fortescue Metals Group-an iron ore giant controlled by billionaire Andrew Forrest-is the largest native title compensation in Australian history. The funds address mining without agreement, destruction of over 140 cultural heritage sites, and cultural distress. Woodley criticizes the compensation as insufficient, highlighting ongoing disputes over economic loss calculations and cultural justice. Fortescue CEO Dino Otranto expressed willingness to improve relations. The controversial decision may face appeal, with the full court ruling due for publication soon.